Blood Tests + MRI for Liver Cancer

(HepQuant Trial)

Overseen by Rafi Kabarriti, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Montefiore Medical Center

No Placebo Group

Trial Summary

What is the purpose of this trial?

This is a pilot and feasibility study assessing the role of quantitative multiparametric MRI and blood-based biomarkers for the measurement of liver function in patients receiving radiation therapy for liver cancer, including hepatocellular carcinoma (HCC), cholangiocarcinoma, or liver metastases regardless of primary histology, that are undergoing photon radiation either in the de-novo or re-irradiation setting. The goal of this study is to prospectively evaluate the feasibility of using quantitative multiparametric MRI to monitor liver function at baseline and following liver radiation therapy.

Research Team

Rafi Kabarriti, MD

Principal Investigator

Montefiore Medical Center

Eligibility Criteria

This trial is for patients with liver cancer, including hepatocellular carcinoma (HCC), cholangiocarcinoma, or liver metastases who are undergoing photon radiation therapy. It's a pilot study to see if MRI scans and blood tests can monitor liver function before and after treatment.

Inclusion Criteria

Concurrent enrollment on other prospective registry or treatment intention trials is allowed

Patient provides study-specific informed consent prior to study entry

My cancer has spread, and it can be targeted for treatment.

Exclusion Criteria

Pregnant or breast-feeding females

Subjects with history of claustrophobia impacting ability to perform MRI during the study

Subjects who fulfill any of the contraindications for MRI; examples include any ferromagnetic material, any metallic shrapnel or fragments or implanted electronic devices contained within the body or metal-containing tattoos

Treatment Details

Interventions

• HepQuant DuO (Diagnostic Test)

Trial Overview The study is testing the use of quantitative multiparametric MRI scans alongside HepQuant DuO blood tests as methods to measure and monitor liver function in patients receiving radiation therapy for various types of liver cancer.

Participant Groups

Group I: Multiparametric MRI scans and HepQuant Duo Test Experimental Treatment 2 Interventions

Group II: Multiparametric MRI scans only Active Control 1 Intervention

Who Is Running the Clinical Trial?

Montefiore Medical Center

Lead Sponsor

Trials

468

Recruited

599,000+

Andrew D. Racine

Montefiore Medical Center

Chief Medical Officer since 1992

MD, PhD from New York University; Undergraduate degree from Harvard University

Philip O. Ozuah

Montefiore Medical Center

Chief Executive Officer since 2019

MD, PhD from New York University

Perspectum

Industry Sponsor

Trials

36

Recruited

13,600+

HepQuant, LLC

Industry Sponsor

Trials

7

Recruited

420+